Details for Patent: 8,357,664

Title:	Antisense antiviral compound and method for treating influenza viral infection
Abstract:	The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5' or 3' terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3' terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.
Inventor(s):	Stein; David A. (Corvallis, OR), Ge; Qing (Santa Cruz, CA), Chen; Jianzhu (Lexington, MA), Iversen; Patrick L. (Corvallis, OR), Moulton; Hong M. (Corvallis, OR)
Assignee:	AVI BioPharma, Inc. (Corvallis, OR) M.I.T. (Cambridge, MA)
Filing Date:	Oct 25, 2005
Application Number:	11/259,434
Claims:	1. A method of treating influenza virus A infection in a mammalian subject, comprising: administering by inhalation to the mammalian subject, a therapeutically effective amount of an antisense conjugate comprising a substantially uncharged antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, and having a targeting sequence of at least 12 contiguous bases that are complementary to SEQ ID NO: 3, and an arginine-rich carrier peptide having the sequence identified by SEQ ID NO: 26 covalently attached to the oligonucleotide, wherein said therapeutically effective amount is an amount effective to reduce viral titer in said subject by at least tenfold compared to an untreated or nonsense-treated control. 2. The method of claim 1, wherein the oligonucleotide analog is 12-40 nucleotide bases in length and targets an AUG start codon of the PB 1viral mRNA. 3. The method of claim 1, wherein the conjugate forms with a complementary-sequence viral target region contained in SEQ ID NO: 3, a heteroduplex having a Tm of dissociation of at least 45.degree. C. 4. The method of claim 1, wherein the intersubunit linkages are uncharged. 5. The method of claim 1, wherein the morpholino subunits are joined by intersubunit linkages in accordance with the structure: ##STR00004## where Y.sub.1.dbd.O, Z.dbd.O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or --NR.sub.2, and wherein each R is independently hydrogen or lower alkyl. 6. The method of claim 5, wherein X is --NR.sub.2 and each R is a lower alkyl. 7. The method of claim 1, wherein the oligonucleotide in the conjugate has the sequence identified by SEQ ID NO:12.